Despite the dismal prognosis conferred by both -7/(del7q) lesions and heterozygous, inactivating CUX1 mutations in myeloid malignancies17–19, which has led to the incorporation of -7/del(7q) lesions in international clinical prognostic scoring systems15,16, there are no specific therapies for the treatment of CUX1-deficient myeloid malignancies. The gene discussed is CUX1; the disease is myeloid neoplasm.